Abrysvo Or Arexvy Market CAGR Forecast Through 2030: Key Trends Shaping Industry Expansion
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
#Abrysvo Or Arexvy Market Size Outlook: How Quickly Will Revenue Expand Through 2030?#_x000D_
The growth experienced during the historic period was primarily due to the unfulfilled requirement for RSV vaccines, the expansion of the aging demographic, the substantial weight of respiratory infections, new regulatory authorizations, and an elevated level of public health consciousness._x000D_
_x000D_
Anticipated expansion during the projection timeframe is driven by an increase in the senior population, a surge in RSV-related hospital admissions, more comprehensive vaccination guidelines, enhanced provider accessibility, and an emphasis on preventative health measures._x000D_
_x000D_
Significant trends anticipated over the forecast duration involve an increasing emphasis on preventing rsv, an uptick in vaccination rates among older adults, the proliferation of adult immunization initiatives, the provision of vaccines through hospitals and community settings, and proactive health management for vulnerable groups._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Abrysvo Or Arexvy Market Growth Momentum: What Factors Are Shaping Demand?#_x000D_
The abrysvo or arexvy market is anticipated to expand due to the rising occurrence of respiratory syncytial virus (RSV) infections. RSV, a common virus, primarily impacts the respiratory system, typically causing mild cold-like symptoms, but can lead to serious conditions in vulnerable groups like infants, the elderly, and those with weakened immune systems. The growing incidence of RSV is fueled by its high contagiousness, recurrent seasonal outbreaks, limited population immunity, and increased vulnerability among demographics such as infants and older adults. Abrysvo contributes to managing RSV infection rates by offering specific vaccines that shield high-risk individuals, including older adults and infants, from severe RSV-related illnesses. For example, data from Oct 2024 by the US-based Centers for Disease Control and Prevention showed that during the 2024-25 season, the hospitalization rate linked to RSV was 3.2 per 100,000 individuals. Consequently, the widespread nature of RSV infections is a key factor boosting the abrysvo or arexvy market’s growth.
Abrysvo Or Arexvy Market Driver: Impact Of Rising Healthcare Expenditure On The Growth Of The Market
_x000D_
The abrysvo or arexvy market is projected to grow as healthcare spending increases. This expenditure represents the financial commitment from governments, private insurers, and individuals to enhance and broaden medical services. Factors contributing to this increase include an aging population, advancements in medical technology, a higher incidence of chronic illnesses, greater demand for healthcare, and rising costs of medications and therapies. Elevated healthcare spending benefits abrysvo or arexvy by directing more financial resources towards sophisticated treatment options, such as biologic therapies. For instance, a May 2023 report from the UK’s Office for National Statistics revealed that between 2022 and 2023, healthcare spending in the UK rose by 5.6%, significantly more than the 0.9% growth seen in 2022, reaching approximately $317.63 billion (£292 billion) in 2023. Thus, increased healthcare expenditure is a significant factor driving the abrysvo or arexvy market forward._x000D_
_x000D_
#Abrysvo Or Arexvy Market Segment Performance And Emerging Opportunities#_x000D_
The abrysvo or arexvy market covered in this report is segmented – _x000D_
_x000D_
1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prevention, Infant Protection_x000D_
2) By Age Group: Adults (18-59 years), Older Adults (60+ years), Pregnant Individuals (32-36 weeks of gestation)_x000D_
3) By End User: Healthcare Providers, Pregnant Individuals, High-Risk Adults_x000D_
_x000D_
#Abrysvo Or Arexvy Market Trends Redefining Industry Growth#_x000D_
Leading companies operating in the abrysvo or arexvy market are concentrating on developing advanced products, such as bivalent prefusion F (RSVpreF) vaccines, to broaden protection, enhance safety, and address high-risk populations. These bivalent RSVpreF vaccines refer to formulations designed to provide immunity against both major RSV subgroups (RSV-A and RSV-B) by targeting the prefusion state of the fusion (F) protein, a key site for neutralizing antibodies. For instance, in October 2024, Pfizer Inc., a US-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for ABRYSVO (RSV Vaccine), a bivalent RSV prefusion F (RSVpreF) vaccine, for preventing lower respiratory tract disease in adults aged 18 to 59 at increased risk, expanding its indication to the broadest adult population. It remains the only approved RSV vaccine for pregnant individuals between 32 and 36 weeks of gestation to protect infants from birth to 6 months._x000D_
_x000D_
#Abrysvo Or Arexvy Market Key Players: Which Companies Lead Industry Competition?#_x000D_
Major companies operating in the abrysvo or arexvy market are Pfizer Inc., GlaxoSmithKline plc (GSK) _x000D_
_x000D_
#View The Full Abrysvo Or Arexvy Market Report:#_x000D_
_x000D_
#Abrysvo Or Arexvy Market Global Footprint: Which Region Leads The Industry?#_x000D_
North America was the largest region in the abrysvo or arexvy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the abrysvo or arexvy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
